Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

140
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
140
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

529
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
529
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-NMDA receptor encephalitis outcomes in a population-based cohort.

Journal of neurology·2026
Same author

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

JAMA neurology·2026
Same author

TRUE-MOGAD Score: A Novel Scoring System to Identify MOGAD Among Positive MOG-IgG Test Results.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Association of epiretinal membranes with disability in people with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Application of the 2024 McDonald Criteria in Individuals With Nonspecific Symptoms or Incidental Imaging Findings in a Multicenter Study.

Neurology·2026
Same author

Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity.

medRxiv : the preprint server for health sciences·2026

Related Experiment Video

Updated: Jul 6, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Rituximab for Multiple Sclerosis: Hiding in Plain Sight

Annette Langer-Gould1, Elias S Sotirchos1, Dennis Bourdette1

  • 1From the Department of Neurology (A.L.-G.), Los Angeles Medical Center, Southern California Permanente Medical Group; Department of Clinical Science (A.L.-G.), Kaiser Permanente School of Medicine, Pasadena, CA; Department of Neurology (E.S.S.), Johns Hopkins University School of Medicine, Baltimore, MD; and Department of Neurology (D.B.), Oregon Health & Science University, Portland.

Neurology
|January 2, 2024
PubMed
Summary

Despite recommendations and WHO listing, rituximab for relapsing multiple sclerosis (RMS) remains underutilized. Stakeholders are urged to improve access and affordability for this essential medicine, contrasting with high-profit therapies.

More Related Videos

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

1.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Related Experiment Videos

Last Updated: Jul 6, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K
Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography
09:41

Imaging CD19+ B Cells in an Experimental Autoimmune Encephalomyelitis Mouse Model using Positron Emission Tomography

Published on: January 20, 2023

1.9K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Area of Science:

  • Neurology
  • Pharmacoeconomics
  • Public Health Policy

Background:

  • Relapsing multiple sclerosis (RMS) treatment landscape is dominated by high-cost disease-modifying therapies.
  • Rituximab, an effective treatment option, faces barriers to access and coverage.
  • Recent policy recommendations and global health listings highlight the need for improved rituximab utilization.

Purpose of the Study:

  • To analyze the current status of rituximab utilization for RMS.
  • To evaluate the impact of recent policy recommendations on rituximab access.
  • To advocate for increased use of rituximab and its biosimilars for RMS.

Main Methods:

  • Review of Institute for Clinical and Economic Review (ICER) policy recommendations from February 2023.
  • Analysis of World Health Organization (WHO) essential medicine listing for rituximab in July 2023.
  • Assessment of persistent barriers to rituximab coverage and utilization.

Main Results:

  • ICER recommended removing barriers to rituximab coverage and endorsing its use for RMS.
  • WHO listed rituximab as an essential medicine for multiple sclerosis.
  • Despite these endorsements, significant barriers to rituximab access and utilization persist.

Conclusions:

  • Rituximab remains underutilized for RMS despite its efficacy and essential medicine status.
  • Stakeholders, including payers, professional societies, and clinicians, must actively promote rituximab coverage and use.
  • Addressing health inequities requires improving access to affordable and effective treatments like rituximab for RMS.